San Diego startup Poseida Therapeutics Inc. has raised $23 million in equity financing according to a recent form filed with the Securities and Exchange Commission.
Poseida Therapeutics (a spinoff of Lexington-based Transposagen Biopharmaceuticals) is currently developing gene therapies for certain kinds of liver disease and cancer. The company also has an alliance with Janssen Biotech to develop various cancer treatments.
An Irish-based life science group, Malin Corp., announced earlier this month that it had acquired a 31 percent stake in Poseida Therapeutics in exchange for an investment of up to $30 million. Malin has invested $20 million in Poseida so far, according to the Malin news release, and has committed to invest an additional $10 million next year, subject to the achievement of certain milestones.
Nishan de Silva, Poseida’s president and chief operating officer, confirmed that the $23 million equity financing includes Malin’s $20 million investment. The SEC statement indicates that the financing came from a total of 14 investors.
Poseida’s Form D was filed with the SEC on December 24, but disclosed that the first date of sale December 15.
